title: A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma.
abstract: Although treatment for hepatocellular carcinoma (HCC) has recently improved, most patients still relapse and die from this disease. The development of new therapeutic and preventive strategies for HCC is, therefore, required. A novel mutant protein (mutein) of human tumor necrosis factor alfa (TNF-alpha mutein F4614, 1SSSRGDSD... 29V ... 155L) was developed to decrease several adverse effects of TNF-alpha. F4614 is known to lack hypotensive effects of human TNF-alpha without losing its anti-tumor effect in mice transplanted with Meth-A sarcoma. Our study investigated the anti-tumor effects of F4614 against hepatoma cells in vitro and in vivo. F4614 significantly inhibited growth of all four tumor cells in vitro. A murine hepatoma cell line, MH134, when incubated in the presence of F4614, exhibited upregulation of surface major histocompatibility complex (MHC) class-I, intercellular adhesion molecule-1 (ICAM-1) and B7-1 molecules, and a decreased proportion of cells in the G2/M phase of the cell cycle. In addition, F4614 induced apoptosis in a significant number of MH134 cells. TNF-alpha and F4614 (5 microg/mouse daily for 5 days) showed similar anti-tumor activities in syngeneic MH134-bearing mice and heterogeneic PLC/PRF/5-bearing athymic nude mice. Intratumoral injection of F4614 or TNF-alpha was more effective than intravenous injection. Immunohistochemical analysis of the tumors treated by F4614 revealed that tumors were surrounded with a large number of Mac-1+ cells and a small number of CD4+ and CD8+ T cells; that suggests that intratumoral injection of F4614 elicited host immunoreactions. Thus, F4614 may be a new strategy for immunotherapy of HCC.
authors.affiliation: Third Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Atarashi
authors.forename: S
authors.initials: S
authors.lastname: Yasumura
authors.forename: S
authors.initials: S
authors.lastname: Nambu
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshio
authors.forename: J
authors.initials: J
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Takahara
authors.forename: K
authors.initials: K
authors.lastname: Higuchi
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Miyata
authors.forename: M
authors.initials: M
authors.lastname: Kato
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000502:physiology; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D000954:Antigens, Surface; D000970:Antineoplastic Agents; C097260:F 4614; D014409:Tumor Necrosis Factor-alpha